Preview

 Пульмонология

Расширенный поиск

ИНТЕРСТИЦИАЛЬНАЯ ПНЕВМОНИЯ С АУТОИММУННЫМИ ПРОЯВЛЕНИЯМИ: СОВМЕСТНЫЙ КОНСЕНСУС ЕВРОПЕЙСКОГО РЕСПИРАТОРНОГО И АМЕРИКАНСКОГО ТОРАКАЛЬНОГО ОБЩЕСТВ

Полный текст:

Аннотация

У многих больных идиопатической интерстициальной пневмонией имеются клинические проявления аутоиммунного заболевания, не соответствующие критериям заболевания соединительной ткани (ЗСТ). Для характеристики таких больных предлагаются различные термины и критерии, а отсутствие единого мнения о терминологии и классификации подобных ситуаций не позволяет выполнять проспективные исследования сопоставимых групп больных. Для выработки консенсуса о терминологии и классификации этих случаев Европейским респираторным и Американским торакальным обществами создана Рабочая группа по недифференцированным формам ЗСТ, сопровождающихся интерстициальными заболеваниями легких, специалистами которой предложено ввести термин «интерстициальная пневмония с аутоиммунными проявлениями» (ИПАП) и диагностические критерии, основанные на сочетании 3 групп признаков: клинических (специфические экстраторакальные симптомы), серологических (специфические аутоантитела) и морфологических (специфические проявления при визуализационных, гистологических исследованиях или исследовании физиологии дыхания). По решению экспертов термин «ИПАП» должен применяться к больным интерстициальными пневмониями и симптомами, позволяющими заподозрить ЗСТ, но не подтверждающими его. Введение нового термина позволит в будущем вовлекать в исследования более однородные когорты больных.

Об авторе

статья Редакционная

Россия


Список литературы

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277–304.

2. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and man agement. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.

3. Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am.J. Respir. Crit. Care Med. 2013; 188: 733–748.

4. Park J.H., Kim D.S., Park I.N. et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease related subtypes. Am. J. Respir. Crit. Care Med. 2007; 175: 705–711.

5. Solomon J.J., Chartrand S., Fischer A. Current approach to connective tissue disease associated interstitial lung disease. Curr. Opin. Pulm. Med. 2014; 20: 449–456.

6. Vij R., Strek M.E. Diagnosis and treatment of connective tissue disease associated interstitial lung disease. Chest. 2013; 143: 814–824.

7. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012; 380: 689–698.

8. Tzelepis G.E., Toya S.P., Moutsopoulos H.M. Occult con nective tissue diseases mimicking idiopathic interstitial pneumonias. Eur. Respir. J. 2008; 31: 11–20.

9. Mittoo S., Gelber A.C., Christopher Stine L. et al. Ascertainment of collagen vascular disease in patients pre senting with interstitial lung disease. Respir. Med. 2009; 103: 1152–1158.

10. Castelino F.V., Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res. Ther. 2010; 12: 213.

11. Castelino F.V., Goldberg H., Dellaripa P.F. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford). 2011; 50: 489–493.

12. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur. Respir. J. 2006; 28: 893–896.

13. Fischer A., Meehan R.T., Feghali Bostwick C.A. et al. Unique characteristics of systemic sclerosis sine scleroder ma associated interstitial lung disease. Chest. 2006; 130: 976–981.

14. Fischer A., Pfalzgraf F.J., Feghali Bostwick C.A. et al. Anti th/to positivity in a cohort of patients with idiopathic pul monary fibrosis. J. Rheumatol. 2006; 33: 1600–1605.

15. Fischer A., Swigris J.J., du Bois R.M. et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest. 2009; 136: 1072–1078.

16. Fischer A., Swigris J.J., du Bois R.M. et al. Anti synthetase syndrome in ANA and anti Jo 1 negative patients presenting with idiopathic interstitial pneumonia. Respir. Med. 2009; 103: 1719–1724.

17. Cottin V. Interstitial lung disease. Eur. Respir. Rev. 2013; 22:26–32.

18. Fischer A., Richeldi L. Cross disciplinary collaboration in connective tissue disease related lung disease. Semin. Respir. Crit. Care Med. 2014; 35: 159–165.

19. Kinder B.W., Collard H.R., Koth L. et al. Idiopathic non specific interstitial pneumonia: lung manifestation of undif ferentiated connective tissue disease? Am. J. Respir. Crit. Care Med. 2007; 176: 691–697.

20. Fischer A., West S.G., Swigris J.J. et al. Connective tissue disease associated interstitial lung disease: a call for clarification. Chest. 2010; 138: 251–256.

21. Vij R., Noth I., Strek M.E. Autoimmune featured interstitial lung disease: a distinct entity. Chest. 2011; 140: 1292–1299.

22. Corte T.J., Copley S.J., Desai S.R. et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur. Respir. J. 2012; 39: 661–668.

23. LeRoy E.C., Black C., Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988; 15: 202–205.

24. LeRoy E.C., Medsger T.A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 2001; 28: 1573–1576.

25. Hervier B., Wallaert B., Hachulla E. et al. Clinical manifestations of anti synthetase syndrome positive for anti alanyl tRNA synthetase (anti PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010; 49: 972–976.

26. Kalluri M., Sahn S.A., Oddis C.V. et al. Clinical profile of anti PL 12 autoantibody. Cohort study and review of the literature. Chest. 2009; 135: 1550–1556.

27. Hirakata M., Suwa A., Takada T. et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl transfer RNA synthetase. Arthritis Rheum. 2007; 56: 1295–1303.

28. Kang E.H., Lee E.B., Shin K.C. et al. Interstitial lung dis ease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005; 44: 1282–1286.

29. Lega J.C., Cottin V., Fabien N. et al. Interstitial lung disease associated with anti PM/Scl or anti aminoacyl tRNA syn thetase autoantibodies: a similar condition? J. Rheumatol. 2010; 37: 1000–1009.

30. Lega J.C., Fabien N., Reynaud Q. et al. The clinical pheno type associated with myositis specific and associated autoantibodies: A meta analysis revisiting the so called antisynthetase syndrome. Autoimmun. Rev. 2014; 13: 883–891.

31. Targoff I.N., Arnett F.C. Clinical manifestations in patients with antibody to PL 12 antigen (alanyl tRNA synthetase). Am. J. Med. 1990; 88: 241–251.

32. Friedman A.W., Targoff I.N., Arnett F.C. Interstitial lung disease with autoantibodies against aminoacyl tRNA syn thetases in the absence of clinically apparent myositis. Semin. Arthritis Rheum. 1996; 26: 459–467.

33. Herrick A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol. 2012; 8: 469–479.

34. Valentini G., Vettori S., Cuomo G. et al. Early systemic sclerosis: short term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Res. Ther. 2012; 14: R188.

35. De Angelis R., Cutolo M., Gutierrez M. et al. Different microvascular involvement in dermatomyositis and systemic sclerosis. A preliminary study by a tight videocapillaroscopic assessment. Clin. Exp. Rheumatol. 2012; 30 (Suppl. 71): S67–S70.

36. Reveille J.D., Solomon D.H. Evidence based guidelines for the use of immunologic tests: anticentromere, Scl 70, and nucleolar antibodies. Arthritis Rheum. 2003; 49: 399–412.

37. Goodwin J.S., Searles R.P., Tung K.S. Immunological responses of healthy elderly population. Clin. Exp. Immunol. 1982; 48: 403–410.

38. Manoussakis M.N., Tzioufas A.G., Silis M.P. et al. High prevalence of anti cardiolipin and other autoantibodies in a healthy elderly population. Clin. Exp. Immunol. 1987; 69: 557–565.

39. Ruffatti A., Rossi L., Calligaro A. et al. Autoantibodies of systemic rheumatic diseases in the healthy elderly. Gerontology. 1990; 36: 104–111.

40. Steen V.D. Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum. 2005; 35: 35–42.

41. Solomon D.H., Kavanaugh A.J., Schur P.H. et al. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002; 47: 434–444.

42. Shanmugam V.K., Swistowski D.R., Saddic N. Comparison of indirect mmunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin. Rheumatol. 2011; 30: 1363–1368.

43. Ando M., Miyazaki E., Ishii T. et al. Incidence of myeloperoxidase anti neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir. Med. 2013; 107: 608–615.

44. Tzelepis G.E., Kokosi M., Tzioufas A. et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur. Respir. J. 2010; 36: 116–121.

45. Tanaka N., Newell J.D., Brown K.K. et al. Collagen vascular diseaserelated lung disease: high resolution computed tomography findings based on the pathologic classification. J. Comput. Assist. Tomogr. 2004; 28: 351–360.

46. Hwang J.H., Misumi S., Sahin H. et al. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J. Comput. Assist. Tomogr. 2009; 33: 410–415.

47. Kim E.J., Elicker B.M., Maldonado F. et al. Usual interstitial pneumonia in rheumatoid arthritis associated interstitial lung disease. Eur. Respir. J. 2010; 35: 1322–1328.

48. Lynch D.A., Travis W.D., Muller N.L. et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005; 236: 10–21.

49. Travis W.D., Hunninghake G., King T.E. Jr. et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am. J. Respir. Crit. Care Med. 2008; 177: 1338–1347.

50. Fukuoka J.L.K. Practical Pulmonary Pathology. A Diagnostic Approach. Philadelphia: Churchill Livingstone; 2005.

51. Leslie K.O., Trahan S., Gruden J. Pulmonary pathology of the rheumatic diseases. Semin. Respir. Crit. Care Med. 2007; 28: 369–378.

52. Pipavath S.J., Lynch D.A., Cool C. et al. Radiologic and pathologic features of bronchiolitis. Am. J. Roentgenol. 2005; 185: 354–363.

53. White E.S., Tazelaar H.D., Lynch J.P. III. Bronchiolar complications of connective tissue diseases. Semin. Respir. Crit. Care Med. 2003; 24: 543–566.

54. Mosca M., Tani C., Carli L. et al. Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract. Res. Clin. Rheumatol. 2012; 26: 73–77.

55. Mosca M., Tani C., Bombardieri S. Undifferentiated con nective tissue diseases (UCTD): a new frontier for rheu matology. Best Pract. Res. Clin. Rheumatol. 2007; 21: 1011–1023.

56. Mosca M., Neri R., Bencivelli W. et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J. Rheumatol. 2002; 29: 2345–2349.

57. Mosca M., Neri R., Bombardieri S. Undifferentiated con nective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin. Exp. Rheumatol. 1999; 17: 615–620.


Для цитирования:


ИНТЕРСТИЦИАЛЬНАЯ ПНЕВМОНИЯ С АУТОИММУННЫМИ ПРОЯВЛЕНИЯМИ: СОВМЕСТНЫЙ КОНСЕНСУС ЕВРОПЕЙСКОГО РЕСПИРАТОРНОГО И АМЕРИКАНСКОГО ТОРАКАЛЬНОГО ОБЩЕСТВ.  Пульмонология. 2016;26(5):529-538.

For citation:


. INTERSTITIAL PNEUMONIAE WITH AUTOIMMUNE MANIFESTATIONS. JOINT CONSENSUS OF THE ERS/ATS. Russian Pulmonology. 2016;26(5):529-538. (In Russ.)

Просмотров: 727


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)